Journal of General Internal Medicine

, Volume 11, Issue 12, pp 765–767

Predictors of mortality after acute hip fracture

  • Mary D. Nettleman
  • Jonathan Alsip
  • Mary Schroder
  • Marilyn Schulte
Brief Reports

Abstract

To identify determinants of mortality after hip fracture, we performed a multicenter, retrospective study of 390 Medicare beneficiaries. Independent predictors of 30-day mortality included a history of congestive heart failure (odds ratio [OR] 32; 95% confidence interval [CI] 5, 192), angina (OR 26; 95% CI 4, 184), or chronic pulmonary disease (OR 11; 95% CI 2, 62). Postoperative use of aspirin was- associated with a reduced risk of mortality (OR 0.24; 95% CI 0.08, 0.70). Cardiovascular events were the presumed cause of 63% of in-hospital deaths. Aspirin may have significant potential to reduce mortality in this population and deserves further study.

Key words

hip fracture mortality outcome aspirin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Myers AH, Robinson EG, Van Natta ML, Michelson JD, Collins K, Baker SP. Hip fractures among the elderly: factors associated with in-hospital mortality. Am J Epidemiol. 1991;134:1128–37.PubMedGoogle Scholar
  2. 2.
    Koval KJ, Zuckerman JD. Functional recovery after fracture of the hip. J Bone Joint Surg. 1994;76-A:751–8.Google Scholar
  3. 3.
    Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2:285–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Schrøder HM, Erlandsen M. Age and sex as determinants of mortality after hip fracture: 3,895 patients followed for 2.5–18.5 years. J Orthop Trauma. 1993;7:525–31.PubMedCrossRefGoogle Scholar
  5. 5.
    Kenzora JE, McCarthy RE, Lowell JD, Sledge C. Hip fracture mortality: relation to age, treatment, preoperative illness, time of surgery, and complications. Clin Orthop Rel Res. 1984;186:45–56.Google Scholar
  6. 6.
    Jencks SF, Wilensky GR. The Health Care Quality Improvement Initiative—a new approach to quality assurance in Medicare. JAMA. 1992;268:900–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic survey. N Engl J Med. 1988;318:1162–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Claget GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest. 1995;108:312S-34S.Google Scholar
  9. 9.
    Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med. 1991;115:591–5.PubMedGoogle Scholar
  10. 10.
    Mossey JM, Mutran E, Knott K, Craik R. Determinants of recovery 12 months after hip fracture: the importance of psychosocial factors. Am J Public Health. 1989;79:279–86.PubMedGoogle Scholar
  11. 11.
    Magaziner J, Simonsick EM, Kashner TM, Hebel JR. Kenzora JE. Survival experience of aged hip fracture patients. Am J Public Health. 1989;79:274–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Fitzgerald JF, Fagan LF, Tierney WM, Dittus RS. Changing patterns of hip fracture care before and after implementation of the prospective payment system. JAMA. 1987;258:218–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med. 1993;327:175–81.Google Scholar
  14. 14.
    Steering committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–35.CrossRefGoogle Scholar
  15. 15.
    Anonymous. Aspirin for prevention of myocardial infarction. Medical Lett. 1995;37:14–6.Google Scholar
  16. 16.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.Google Scholar
  17. 17.
    Krumholz HM, Radford MJ, Ellerbeck E, et al. Aspirin in the treatment of acute myocardial infection in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation. 1995;92:2841–7.PubMedGoogle Scholar
  18. 18.
    MacMahon S, Rodgers A, Collins R, Farrell B. Antiplatelet therapy to prevent thrombosis after hip fracture: rationale for a randomised trial. J Bone Joint Surg Br. 1994;76-B:521–4.Google Scholar
  19. 19.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235–46.Google Scholar
  20. 20.
    Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994;271:1780–5.PubMedCrossRefGoogle Scholar

Copyright information

© Blackwell Science, Inc. 1996

Authors and Affiliations

  • Mary D. Nettleman
    • 1
    • 2
  • Jonathan Alsip
    • 2
  • Mary Schroder
    • 2
  • Marilyn Schulte
    • 2
  1. 1.the Division of General Medicine, Department of Internal Medicine, Medical College of VirginiaVirginia Commonwealth UniversityRichmond
  2. 2.the Iowa Foundation for Medical CareWest Des MoinesUSA

Personalised recommendations